News
Anlotinib plus penpulimab has demonstrated encouraging activity and safety in a phase 2 study. In this phase 3 trial, we aimed to assess whether the combination of anlotinib plus penpulimab improved ...
An enhanced accuracy finite-control-set model-predictive control (FCS-MPC) is presented in this letter. The main advantage of conventional FCS-MPC is its ease in achieving multiobjective optimization ...
The phase 3 CONTACT-02 study was designed to evaluate the efficacy and safety of cabozantinib plus atezolizumab versus ARPI switch in patients with mCRPC and measurable extrapelvic soft-tissue ...
The input current distortion issue associated with discontinuous pulsewidth modulation (DPWM) is a significant concern for three-level Vienna rectifiers. While larger dc-link electrolytic capacitors ...
What is today’s moon phase? As of Thursday, July 3, the moon phase is Waxing Gibbous. According to NASA's Daily Moon Observation, 57% of the moon will be lit up and visible to us on Earth.
Biotech 4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline By James Waldron Jul 3, 2025 4:52am 4D Molecular Therapeutics Cell & Gene Therapy layoffs wet AMD ...
Topline results were announced from a phase 3 study evaluating secukinumab in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) that target estrogen receptors through new mechanisms, highlighting modest ...
Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially in patients with ESR1 mutations—from proteolysis-targeting chimeras ...
The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial. The study is ongoing across sites in the United States, the United Kingdom, France, ...
Aker BP announces that the Johan Sverdrup partnership has made a final investment decision for Phase 3 of the field development. The project includes new subsea infrastructure that will increase ...
South Korean company HLB Therapeutics has announced that its US subsidiary, ReGenTree, failed to meet the primary end point in a European phase 3 trial (SEER-3) of RGN-259, a thymosin beta-4–based eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results